A phase I study of etoposide phosphate plus paclitaxel

Area of Science:

• Oncology
• Pharmacology
• Cancer Therapeutics

Background:

• Etoposide phosphate (Etopophos) is a water-soluble derivative of etoposide, offering improved administration compared to the poorly soluble parent drug.
• Etoposide phosphate is rapidly converted to etoposide in vivo, maintaining similar pharmacokinetic profiles.
• The combination of etoposide and paclitaxel is being investigated due to their distinct mechanisms of action and overlapping activity against various malignancies.

Purpose of the Study:

• To evaluate the safety and determine the maximum tolerated doses (MTD) of a combination regimen involving etoposide phosphate and paclitaxel.
• To assess the toxicities associated with this novel combination therapy.
• To explore the potential anticancer activity of the etoposide phosphate and paclitaxel combination.

Main Methods:

• A Phase I clinical trial was conducted to assess the combination of paclitaxel (3-hour infusion) and etoposide phosphate (5-minute infusion) administered daily for 3 days every 21 days.
• Dose escalation was performed to identify the MTD for each drug in combination.
• Patient cohorts included those with and without extensive prior chemotherapy or radiotherapy.

Main Results:

• Etoposide phosphate demonstrated dose-limiting neutropenia, with recommended doses of 100 mg/m²/day for previously untreated patients and 75 mg/m²/day for heavily pretreated patients.
• Pharmacokinetic studies confirmed that etoposide phosphate is bioequivalent to etoposide.
• The ongoing Phase I study aims to establish the MTD and toxicity profile of the combination therapy.

Conclusions:

• Etoposide phosphate offers a more convenient administration route than etoposide due to its water solubility.
• The combination of etoposide phosphate and paclitaxel is under investigation as a potential new cancer treatment strategy.
• Further studies are needed to fully elucidate the efficacy and safety of this combination regimen.